1Becker PM. Pharmacologic and nonpharmacologic treatment of insomnia. Neurol Clin, 2005 , 23 (4) : 1149-1163.
2Curry DT, Eisenstein RD, Walsh JK. Pharmacologic management of insomnia : past, present, and future. Psychiatr Clin N Am, 2006, 29(4) : 871-893.
3Markov D, Goldman M. Normal sleep and circadian rhythms, neurobiologic mechanisms underlying sleep and wakefulness. Psychiatr Clin N Am, 2006, 29 (4) : 841 -853.
4Peterson M J, Benca RM. Sleep in mood disorder. Psychiatr Clin N Am, 2006, 29(4) : 1009-1032.
5Roth T. Introduction : understanding neuronal pathways : novel targets for the management of insomnia. J Clin Psychiatry, 2007, 68 ( Suppl 5 ) : 4-5.
6Steiger A. neurochemical regulation of sleep. J Psychiatric Res, 2007, 41(7) : 537-552.
7Lee KS, Alvarenga TA, Guindalini C, et al. Validation of commonly used reference genes for sleep-related gene expression studies. BMC Mol Biol, 2009, 10: 45.
8Tinuner M, Cesnulevicius K, Winkler C, et al. Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesion. J Neurosci, 2007, 27(3 ) : 459-471.
9Wu J, Holstein JD, Upadhyay G, et al. Purinergic receptorstimulated IP3-mediated Ca^2+ release enhances neuroprotection by increasing astrocyte mitochondrial metabolism during aging. J Neurosci, 2007, 27(24): 6510-6520.
10Fiacco TA, Mccarthy KD. Astrocyte calcium elevations: properties, propagation, and effects on brain signaling. Glia, 2006, 54(7) : 676-690.
